Analyst Price Target is $2.64
▲ +288.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for IceCure Medical in the last 3 months. The average price target is $2.64, with a high forecast of $2.77 and a low forecast of $2.50. The average price target represents a 288.13% upside from the last price of $0.68.
Current Consensus is
Hold
The current consensus among 4 investment analysts is to hold stock in IceCure Medical. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Read More